Journal
BMC CANCER
Volume 18, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12885-018-5015-0
Keywords
Plasma-cell neoplasm; Targeted cancer therapy; Small-drug inhibitor; Cellular senescence
Categories
Funding
- National Natural Science Foundation of China (NSFC) [81500166, 81600177, 81770220, 81670200]
- Natural Science Foundation of Jiangsu Province [BK20160048, BK20161041]
- NIH [R21CA187388, R01CA151354, R01CA152105]
- Multiple Myeloma Research Foundation
- International Myeloma Foundation
- American Society of Hematology (ASH) Bridge Funding Program
- University of Iowa Holden Comprehensive Cancer Center [P30CA086862]
- ASH's Bridge Grant Program
Ask authors/readers for more resources
Background: Following up on previous work demonstrating the involvement of the transcription factor forkhead box M1 (FOXM1) in the biology and outcome of a high-risk subset of newly diagnosed multiple myeloma (nMM), this study evaluated whether FOXM1 gene expression may be further upregulated upon tumor recurrence in patients with relapsed multiple myeloma (rMM). Also assessed was the hypothesis that increased levels of FOXM1 diminish the sensitivity of myeloma cells to commonly used myeloma drugs, such as the proteasome inhibitor bortezomib (Bz) and the DNA intercalator doxorubicin (Dox). Methods: FOXM1 message was evaluated in 88 paired myeloma samples from patients with nMM and rMM, using gene expression microarrays as measurement tool. Sources of differential gene expression were identified and outlier analyses were performed using statistical methods. Two independent human myeloma cell lines (HMCLs) containing normal levels of FOXM1 (FOXM1(N)) or elevated levels of lentivirus-encoded FOXM1 (FOXM1(Hi)) were employed to determine FOXM1-dependent changes in cell proliferation, survival, efflux-pump activity, and drug sensitivity. Levels of retinoblastoma (Rb) protein were determined with the assistance of Western blotting. Results: Upregulation of FOXM1 occurred in 61 of 88 (69%) patients with rMM, including 4 patients that exhibited >20-fold elevated expression peaks. Increased FOXM1 levels in FOXM1(Hi) myeloma cells caused partial resistance to Bz (1.9-5.6 fold) and Dox (1.5-2.9 fold) in vitro, using FOXM1(N) myeloma as control. Reduced sensitivity of FOXM1(Hi) cells to Bz was confirmed in vivo using myeloma-in-mouse xenografts. FOXM1-dependent regulation of total and phosphorylated Rb agreed with a working model of myeloma suggesting that FOXM1 governs both chromosomal instability (CIN) and E2F-dependent proliferation, using a mechanism that involves interaction with NIMA related kinase 2 (NEK2) and cyclin dependent kinase 6 (CDK6), respectively. Conclusions: These findings enhanced our understanding of the emerging FOXM1 genetic network in myeloma and provided preclinical support for the therapeutic targeting of the FOXM1-NEK2 and CDK4/6-Rb-E2F pathways using small-drug CDK and NEK2 inhibitors. Clinical research is warranted to assess whether this approach may overcome drug resistance in FOXM1(Hi) myeloma and, thereby, improve the outcome of patients in which the transcription factor is expressed at high levels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available